HUMALOG MIX 25 (CARTRIDGE) 75 UNIT
INSULIN LISPRO PROTAMINE SUSPENSION : 75 UNIT INSULIN LISPRO : 25 UNIT · DIN 02240294 · ELI LILLY CANADA INC
Health Canada status: MARKETED
What is HUMALOG MIX 25 (CARTRIDGE)?
HUMALOG MIX 25 (CARTRIDGE) 75 UNIT contains INSULIN LISPRO PROTAMINE SUSPENSION : 75 UNIT INSULIN LISPRO : 25 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02240294, held by ELI LILLY CANADA INC, supplied as SUSPENSION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 05-Jul-1999. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is HUMALOG MIX 25 (CARTRIDGE) used for?
HUMALOG (insulin lispro injection), HUMALOG MIX25 (25% insulin lispro injection, 75% insulin lispro protamine suspension), and HUMALOG MIX50 (50% insulin lispro injection, 50% insulin lispro protamine suspension) are indicated for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. HUMALOG insulins are also indicated for the initial stabilization of diabetes mellitus.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is HUMALOG MIX 25 (CARTRIDGE) called?
The same molecule, INSULIN LISPRO, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Actrapid HM (ge) | Latin | South Africa |
| Insuman Rapid | Latin | Norway |
| Humulin NPH | Latin | Norway |
| Humulin NPH KwikPen | Latin | Norway |
| Insuman Infusat | Latin | Norway |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02240294 |
|---|---|
| Brand name | HUMALOG MIX 25 (CARTRIDGE) |
| Generic / active ingredient | INSULIN LISPRO PROTAMINE SUSPENSION : 75 UNIT INSULIN LISPRO : 25 UNIT |
| Manufacturer | ELI LILLY CANADA INC |
| Strength | 75 UNIT |
| Dosage form | SUSPENSION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Schedule D |
| ATC code | A10AD04 INSULIN LISPRO |
| AHFS class | 68:20.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 05-Jul-1999 |
| Original market date | 2000-01-10 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02240294 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2240294 |
| Brand name | HUMALOG MIX 25 (CARTRIDGE) |
| Active ingredient / INN | INSULIN LISPRO PROTAMINE SUSPENSION : 75 UNIT INSULIN LISPRO : 25 UNIT |
| ATC code | A10AD04 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A10 |
| AHFS class | 68:20.08 |
| Health Canada schedule | Schedule D |
| Biosimilar biologic | No |
| Market authorization holder | ELI LILLY CANADA INC |
How is it stored and handled?
See STORAGE AND STABILITY section
Which pack is which?
| Strength on the label | 75 UNIT |
|---|---|
| Dosage form | SUSPENSION |
| Route | SUBCUTANEOUS |
| Storage | See STORAGE AND STABILITY section |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code A10AD04 INSULIN LISPRO. 4 of 11 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| HUMALOG MIX 25 (KWIKPEN) | 25 UNIT | SUSPENSION | ELI LILLY CANADA INC | MARKETED | DIN 02403420 |
| HUMALOG MIX 50 (CARTRIDGE) | 50 UNIT | SUSPENSION | ELI LILLY CANADA INC | MARKETED | DIN 02240297 |
| HUMALOG MIX 50 (KWIKPEN) | 50 UNIT | SUSPENSION | ELI LILLY CANADA INC | MARKETED | DIN 02403439 |
| HUMALOG MIX 25 (PEN) | 75 UNIT | SUSPENSION | ELI LILLY CANADA INC | CANCELLED POST MARKET | DIN 02240295 |
| LYUMJEV | 100 UNIT | SOLUTION | ELI LILLY CANADA INC | APPROVED | DIN 02520184 |
| LYUMJEV | 300 UNIT / 3 ML | SOLUTION | ELI LILLY CANADA INC | APPROVED | DIN 02520192 |
| LYUMJEV JUNIOR KWIKPEN | 300 UNIT / 3 ML | SOLUTION | ELI LILLY CANADA INC | APPROVED | DIN 02520214 |
| LYUMJEV KWIKPEN | 300 UNIT / 3 ML | SOLUTION | ELI LILLY CANADA INC | APPROVED | DIN 02520206 |
| LYUMJEV KWIKPEN | 600 UNIT / 3 ML | SOLUTION | ELI LILLY CANADA INC | APPROVED | DIN 02520230 |
| LYUMJEV TEMPO PEN | 300 UNIT / 3 ML | SOLUTION | ELI LILLY CANADA INC | APPROVED | DIN 02520222 |
Who else supplies INSULIN LISPRO worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. INSULIN LISPRO appears in 441 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does INSULIN LISPRO cost around the world?
INSULIN LISPRO is listed on 3 national price registers Nexara tracks, across 49 pack listings published on 3 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Greece | producer price (ex-factory) | 41 | 41 | 03 Sep 2026 |
| Norway | max AUP (pharmacy retail) | 5 | 6 | 07 Sep 2026 |
| South Africa | single exit price | 1 | 2 | 01 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.